Paper34907910
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.
Yarchoan M and 28 others. J Clin Invest, 2021. Cited by 109 papers, by iCite.
Cite this record
ConductScience Library. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. Papers, record 34907910. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34907910
- Disease
- cholangiocarcinoma144 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.
- PubMed
- Publication types
- Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Biliary Tract Neoplasms | Major topic |
| Aged | |
| Antibodies, Monoclonal, Humanized | |
| Azetidines | |
| Disease-Free Survival | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Piperidines | |
| Progression-Free Survival |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| UL1 TR001863 | NCATS NIH HHS | United States | UL1TR001863 | PubMed | NIH RePORTER |
| UM1 CA186712 | NCI NIH HHS | United States | UM1CA186712 | PubMed | NIH RePORTER |
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed | NIH RePORTER |
| P30 CA016058 | NCI NIH HHS | United States | P30CA016058 | PubMed | NIH RePORTER |
| UM1 CA186717 | NCI NIH HHS | United States | UM1CA186717 | PubMed | NIH RePORTER |
| UM1 CA186691 | NCI NIH HHS | United States | UM1CA186691 | PubMed and NIH | NIH RePORTER |
| K12 CA086913 | NCI NIH HHS | United States | K12CA086913 | PubMed | NIH RePORTER |
| R01 CA228414 | NCI NIH HHS | United States | R01CA228414 | PubMed and NIH | NIH RePORTER |
| P50 CA062924 | NCI NIH HHS | United States | P50CA062924 | PubMed and NIH | NIH RePORTER |
| P30 CA006973 | NCI NIH HHS | United States | P30CA006973 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03201458 | Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer | Derived from the trial | Yes |
Source ClinicalTrials.gov
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31257581 | Targeting Treg cells in cancer immunotherapy. | Eur J Immunol | 2019 | https://conductscience.org/library/papers/31257581 | PubMed |
| 2 | 25436118 | Second-line systemic treatment for advanced cholangiocarcinoma. | J Gastrointest Oncol | 2014 | https://conductscience.org/library/papers/25436118 | PubMed |
| 3 | 32234665 | Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer. | Eur J Cancer | 2020 | https://conductscience.org/library/papers/32234665 | PubMed |
| 4 | 34339623 | Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. | Lancet Oncol | 2021 | https://conductscience.org/library/papers/34339623 | PubMed |
| 5 | 24244023 | The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. | J Immunol | 2013 | https://conductscience.org/library/papers/24244023 | PubMed |
| 6 | 32352498 | A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32352498 | PubMed |
| 7 | 19395114 | A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment. | J Hepatol | 2009 | https://conductscience.org/library/papers/19395114 | PubMed |
| 8 | 26742998 | Cancer statistics, 2016. | CA Cancer J Clin | 2016 | https://conductscience.org/library/papers/26742998 | PubMed |
| 9 | 28928158 | Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28928158 | PubMed |
| 10 | 24769639 | Second-line chemotherapy in advanced biliary cancer: a systematic review. | Ann Oncol | 2014 | https://conductscience.org/library/papers/24769639 | PubMed |
| 11 | 29848569 | Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29848569 | PubMed |
| 12 | 28441383 | The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. | Br J Cancer | 2017 | https://conductscience.org/library/papers/28441383 | PubMed |
| 13 | 31003911 | Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/31003911 | PubMed |
| 14 | 32416072 | Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. | Lancet Oncol | 2020 | https://conductscience.org/library/papers/32416072 | PubMed |
| 15 | 25589619 | The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25589619 | PubMed |
| 16 | 31454426 | Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes. | Cancer | 2019 | https://conductscience.org/library/papers/31454426 | PubMed |
| 17 | 33547983 | Tumor and Systemic Immunomodulatory Effects of MEK Inhibition. | Curr Oncol Rep | 2021 | https://conductscience.org/library/papers/33547983 | PubMed |
| 18 | 7644477 | A synthetic inhibitor of the mitogen-activated protein kinase cascade. | Proc Natl Acad Sci U S A | 1995 | https://conductscience.org/library/papers/7644477 | PubMed |
| 19 | 30563938 | Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30563938 | PubMed |
| 20 | 11391522 | Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. | Hepatology | 2001 | https://conductscience.org/library/papers/11391522 | PubMed |
Cited by68
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 109 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42660998 | Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy. | Nat Rev Cardiol | 2026 | https://conductscience.org/library/papers/42660998 | PubMed |
| 42511572 | Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42511572 | PubMed |
| 42377085 | A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42377085 | PubMed |
| 42115188 | The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial. | Nat Commun | 2026 | https://conductscience.org/library/papers/42115188 | PubMed |
| 42113099 | Exercise-induced modulation of the unfolded protein response: a therapeutic avenue for muscle wasting disorders. | J Physiol Biochem | 2026 | https://conductscience.org/library/papers/42113099 | PubMed |
| 42110477 | CAR-T cells directed toward PD-L1 demonstrate potent, antigen-specific activity against cholangiocarcinoma: A proof of concept study. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42110477 | PubMed |
| 41756323 | Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms. | Front Oncol | 2026 | https://conductscience.org/library/papers/41756323 | PubMed |
| 41373405 | A Comprehensive Analysis of Novel Variations Associated with Bile Duct Cancer: Insights into Expression, Methylation, and 3D Protein Structure. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41373405 | PubMed |
| 41226789 | Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41226789 | PubMed |
| 41220768 | Recent advancements in systemic therapy for biliary tract cancers: a literature review. | J Gastrointest Oncol | 2025 | https://conductscience.org/library/papers/41220768 | PubMed |
| 41206885 | Use of Neoadjuvant Immunotherapy in Malignant Peritoneal Mesothelioma as a Bridge to Surgical Intervention: A Case Report. | Am J Case Rep | 2025 | https://conductscience.org/library/papers/41206885 | PubMed |
| 41178912 | Global gene expression landscape of gallbladder cancer and advances in targeted therapeutic strategies. | World J Clin Oncol | 2025 | https://conductscience.org/library/papers/41178912 | PubMed |
| 41143064 | Targeting the tumor microenvironment in cholangiocarcinoma to improve immune checkpoint blockade: potential strategies and translational pre-clinical models. | Clin Transl Immunology | 2025 | https://conductscience.org/library/papers/41143064 | PubMed |
| 40972018 | Development of a murine tumor-infiltrating lymphocyte therapy model for cholangiocarcinoma. | J Immunol | 2026 | https://conductscience.org/library/papers/40972018 | PubMed |
| 40940908 | Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next? | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40940908 | PubMed |
| 40861435 | Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies. | Front Immunol | 2025 | https://conductscience.org/library/papers/40861435 | PubMed |
| 40830299 | Enhancer regulation in cancer: from epigenetics to m6A RNA modification. | Arch Pharm Res | 2025 | https://conductscience.org/library/papers/40830299 | PubMed |
| 40760243 | Efficacy and safety of targeted therapy and immune checkpoint inhibitors in patients with advanced or metastatic biliary tract cancer: a meta-analysis of and sequential analysis of trials. | Hepatol Int | 2025 | https://conductscience.org/library/papers/40760243 | PubMed |
| 40668526 | Improving the Accumulation and Solubility of Human Interferon-γ (hIFN-γ) in Escherichia coli: A Fusion Protein-Based Method and Network Pharmacology Analysis. | Appl Biochem Biotechnol | 2025 | https://conductscience.org/library/papers/40668526 | PubMed |
| 40590857 | Tumor site influences efficacy of MEKi and immunotherapy combinations in a preclinical model of cholangiocarcinoma. | Hepatology | 2026 | https://conductscience.org/library/papers/40590857 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BTLA | 151888 | PubTator's text mining | https://conductscience.org/library/genes/151888 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CD8A | 925 | PubTator's text mining | https://conductscience.org/library/genes/925 | NCBI Gene |
| FOXP3 | 50943 | PubTator's text mining | https://conductscience.org/library/genes/50943 | NCBI Gene |
| LAG3 | 3902 | PubTator's text mining | https://conductscience.org/library/genes/3902 | NCBI Gene |
| MAP2K7 | 5609 | PubTator's text mining | https://conductscience.org/library/genes/5609 | NCBI Gene |
| VSIR | 64115 | PubTator's text mining | https://conductscience.org/library/genes/64115 | NCBI Gene |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| COBIMETINIB | CHEMBL2146883 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2146883 | ChEMBL |
| ATEZOLIZUMAB | CHEMBL3707227 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL3707227 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34907910
GET https://conductscience.org/api/papers/v1/34907910/authors?page=2